Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (canceled)

2. (canceled)

3. (canceled)

4. (canceled)

5. (currently amended) A method of testing for a cedar pollen allergy, said method comprising the steps of:

   (a) preparing T cells from a subject,

   (b) preparing an RNA sample from said T cells,

   (c) conducting hybridization with said RNA sample using a ~~nucleic acid that specifically hybridizes to~~ probe comprising nucleotides of gene 513, wherein the nucleotides consist of a segment of nucleotides between positions 36[[-]] and 1171 of SEQ ID NO:1 or the complement thereof ~~as a probe,~~ wherein said probe is labeled, and

   (d) measuring the amount of RNA that is derived from said subject and that hybridizes with said probe, and comparing said amount with the amount of RNA of a control group which has ~~normal level~~ 3.5 AU/mL or less of cedar pollen specific IgE, wherein if the amount of gene 513 RNA is significantly higher in a sample from the subject than in the control group, then the subject is determined to have a cedar pollen allergy.

6. (currently amended) A method of testing for a cedar pollen allergy, said method comprising the steps of:

   (a) preparing T cells from a subject,

   (b) preparing an RNA sample from said T cells,

(c) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

(d) conducting polymerase chain reaction (PCR) using said cDNA as template and a primer that ~~specifically hybridizes to~~ comprising nucleotides of gene 513, wherein the nucleotides consist of a segment of nucleotides between positions 36[[-]] and1171 of SEQ ID NO: 1 or the complement thereof, and

(e) comparing the amount of DNA amplified by said PCR with a control group which has ~~normal level~~ 3.5 AU/mL or less of cedar pollen specific IgE, wherein if the amount of gene 513 cDNA is significantly higher in a sample from the subject than in the control group, then the subject is determined to have a cedar pollen allergy.

7. (original) The method of claim 6, wherein said PCR is carried out by a PCR amplification monitoring method.

8. (previously presented) The method of claims 5, wherein said T cells are prepared from peripheral blood of said subject.

9. (canceled)

10. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) administering a test compound to a pollen allergy model animal and stimulating with pollen antigen,

(b) preparing T cells from said model animal,

(c) preparing an RNA sample from said T cells,

(d) conducting hybridization with said RNA sample using the DNA of claim 3 as probe, wherein said DNA is labeled,

(e) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and

(f) selecting a compound that reduces the amount of said RNA measured in (e), compared to a control (a case where said test compound is not administered).

11. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for

an allergic disease, said method comprising the steps of:

(a) administering a test compound to a pollen allergy model animal and stimulating with pollen antigen,

(b) preparing T cells from said model animal,

(c) preparing an RNA sample from said T cells,

(d) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

(e) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and

(f) selecting a compound that reduces the amount of said DNA amplified in (e), compared to a control (a case where said test compound is not administered).

12. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) administering a test compound to a pollen allergy model animal,

(b) preparing lymphocytes from said model animal,

(c) stimulating said lymphocytes with pollen antigen,

(d) separating T cells from said lymphocytes stimulated with said antigen,

(e) preparing an RNA sample from said T cells,

(f) conducting hybridization with said RNA sample using the DNA that hybridizes to SEQ ID NO:1 as probe, wherein said DNA is labeled,

(g) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and

(h) selecting a compound that reduces the amount of said RNA measured in (g), compared to a control (a case where said test compound is not administered).

13. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) administering a test compound to a pollen allergy model animal,

(b) preparing lymphocytes from said model animal,

(c) stimulating said lymphocytes with pollen antigen;

(d) separating T cells from said lymphocytes stimulated with said antigen,

(e) preparing an RNA sample from said T cells,

(f) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

(g) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and

(h) selecting a compound that reduces the amount of said DNA amplified in (g), compared to a control (a case where said test compound is not administered).

14. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) preparing lymphocytes from a pollen allergy model animal or from a human having a pollen allergy,

(b) stimulating said lymphocytes with pollen antigen in the presence of a test compound,

(c) separating T cells from said lymphocytes stimulated with said antigen,

(d) preparing an RNA sample from said T cells,

(e) conducting hybridization with said RNA sample using the DNA of claim 3 as probe, wherein said DNA is labeled,

(f) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and

(g) selecting a compound that reduces the amount of said RNA measured in (f), compared to a control (a case where said test compound is not administered).

15. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) preparing lymphocytes from a pollen allergy model animal or from a human having a pollen allergy,

(b) stimulating said lymphocytes with pollen antigen in the presence of a test compound,

(c) separating T cells from said lymphocytes stimulated with said antigen,

(d) preparing an RNA sample from said T cells,

(e) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

(f) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and

(g) selecting a compound that reduces the amount of said DNA amplified in (f), compared to a control (a case where said test compound is not administered).

16. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) stimulating a T-cell line with a lymphocyte-stimulating substance in the presence of a test compound,

(b) preparing an RNA sample from said stimulated T-cell line,

(c) conducting hybridization with said RNA sample using the DNA of claim 3 as probe, wherein said DNA is labeled,

(d) measuring the amount of RNA that is derived from said T-cell line and that hybridizes with said DNA, and

(e) selecting a compound that reduces the amount of said RNA measured in (d), compared to a control (a case where said test compound is not administered).

17. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) stimulating a T-cell line with a lymphocyte-stimulating substance in the presence of a test compound,

(b) preparing an RNA sample from said stimulated T-cell line,

(c) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

(d) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and

(e) selecting a compound that reduces the amount of said DNA amplified in (d),

compared to a control (a case where said test compound is not administered).

18. (withdrawn) The method of claim 10, wherein said T cells are prepared from peripheral blood of said pollen allergy model animal.

19. (withdrawn) The method of claim 12, wherein said lymphocytes are prepared from peripheral blood.

20. (withdrawn) The method of claim 10, wherein said allergic disease is a cedar pollen allergy.

21. (new). The method of claim 5, wherein the probe consists of at least 15 nucleotides between positions 36 and 1171 of SEQ ID NO:1 and the complement thereof.

22. (new). The method of claim 6, wherein the primer consists of at least 15 nucleotides between positions 36 and 1171 of SEQ ID NO:1 and the complement thereof.